Brendon Stubbs1, Alex J Mitchell2, Marc De Hert3, Christoph U Correll4, Andy Soundy5, Marc Stroobants6, Davy Vancampfort7. 1. Faculty of Education and Health, University of Greenwich, Southwood Site, Avery Hill Road, Eltham, London SE9 2UG, UK. Electronic address: b.stubbs@greenwich.ac.uk. 2. Department of Psycho-oncology, University of Leicester, Leicester LE1 5WW, UK. Electronic address: ajm80@le.ac.uk. 3. University Psychiatric Centre, KU Leuven, KU Leuven Departement of Neurosciences, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium. Electronic address: marc.de.hert@uc-kortenberg.be. 4. Zucker Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY 11004, USA. Electronic address: CCorrell@NSHS.edu. 5. Department of Physiotherapy, University of Birmingham, Birmingham B15 2TT, UK. Electronic address: a.a.soundy@bham.ac.uk. 6. University Psychiatric Centre, KU Leuven, KU Leuven Departement of Neurosciences, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium. Electronic address: med.bib@uc-kortenberg.be. 7. University Psychiatric Centre, KU Leuven, KU Leuven Departement of Neurosciences, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium; KU Leuven Department of Rehabilitation Sciences, Tervuursevest 101, B-3001 Leuven, Belgium. Electronic address: Davy.Vancampfort@uc-kortenberg.be.
Abstract
BACKGROUND: People with schizophrenia frequently have physical comorbidities that can cause pain. Experimental studies report reduced pain sensitivity among schizophrenia patients, but it remains unclear if clinically relevant pain is less prevalent in schizophrenia. METHOD: We systematically searched major electronic databases from inception till 03/2014. Articles were included that reported the prevalence of clinical pain in people with schizophrenia. Two independent authors conducted searches, completed methodological quality assessment and extracted data. A random effects relative risks (RR) meta-analysis was conducted to determine the prevalence of all-cause and specific pain in schizophrenia, and the relative prevalence compared to the general population, and to assess moderators. RESULTS: Altogether, 14 studies were included encompassing 242,703 individuals with schizophrenia (30.2-55.8 years) and 4,259,221 controls. Different types of pain were considered. The overall pooled prevalence of clinical pain in people with schizophrenia was 34.7% (95% CI=23.6-46.6). In the comparative analysis involving 7 studies with controls, the RR was 0.99 (95% CI=0.83-1.19). The pooled prevalence of headache among 94,043 individuals with schizophrenia was 29.9% (95% CI=3-69%) and the RR compared to 4,248,284 controls was 1.32 (95% CI=0.85-2.07). In moderator analyses, neither age, sex, study quality or pain assessment method influenced pain prevalence. CONCLUSION: Clinical pain affects a third of people with schizophrenia and levels are similar with age- and sex-comparable controls. Future research is needed to determine if similar clinical pain prevalences in schizophrenia occur despite having more painful conditions, resulting from under-reporting, higher pain thresholds or lower help seeking behaviours.
BACKGROUND:People with schizophrenia frequently have physical comorbidities that can cause pain. Experimental studies report reduced pain sensitivity among schizophreniapatients, but it remains unclear if clinically relevant pain is less prevalent in schizophrenia. METHOD: We systematically searched major electronic databases from inception till 03/2014. Articles were included that reported the prevalence of clinical pain in people with schizophrenia. Two independent authors conducted searches, completed methodological quality assessment and extracted data. A random effects relative risks (RR) meta-analysis was conducted to determine the prevalence of all-cause and specific pain in schizophrenia, and the relative prevalence compared to the general population, and to assess moderators. RESULTS: Altogether, 14 studies were included encompassing 242,703 individuals with schizophrenia (30.2-55.8 years) and 4,259,221 controls. Different types of pain were considered. The overall pooled prevalence of clinical pain in people with schizophrenia was 34.7% (95% CI=23.6-46.6). In the comparative analysis involving 7 studies with controls, the RR was 0.99 (95% CI=0.83-1.19). The pooled prevalence of headache among 94,043 individuals with schizophrenia was 29.9% (95% CI=3-69%) and the RR compared to 4,248,284 controls was 1.32 (95% CI=0.85-2.07). In moderator analyses, neither age, sex, study quality or pain assessment method influenced pain prevalence. CONCLUSION: Clinical pain affects a third of people with schizophrenia and levels are similar with age- and sex-comparable controls. Future research is needed to determine if similar clinical pain prevalences in schizophrenia occur despite having more painful conditions, resulting from under-reporting, higher pain thresholds or lower help seeking behaviours.
Authors: Jessica M Brooks; Courtney A Polenick; William Bryson; John A Naslund; Brenna N Renn; Nicole M Orzechowski; Margaret Almeida; Stephen J Bartels Journal: Aging Ment Health Date: 2018-01-22 Impact factor: 3.658
Authors: Teresa M Karrer; Danielle S Bassett; Birgit Derntl; Oliver Gruber; André Aleman; Renaud Jardri; Angela R Laird; Peter T Fox; Simon B Eickhoff; Olivier Grisel; Gaël Varoquaux; Bertrand Thirion; Danilo Bzdok Journal: Hum Brain Mapp Date: 2019-07-16 Impact factor: 5.038
Authors: Brendon Stubbs; Ai Koyanagi; Felipe Schuch; Joseph Firth; Simon Rosenbaum; Fiona Gaughran; James Mugisha; Davy Vancampfort Journal: Schizophr Bull Date: 2017-05-01 Impact factor: 9.306
Authors: Brendon Stubbs; Ai Koyanagi; Nicola Veronese; Davy Vancampfort; Marco Solmi; Fiona Gaughran; André F Carvalho; John Lally; Alex J Mitchell; James Mugisha; Christoph U Correll Journal: BMC Med Date: 2016-11-22 Impact factor: 8.775
Authors: Davy Vancampfort; Brendon Stubbs; Marc De Hert; Christy du Plessis; Caleb Ademola Omuwa Gbiri; Jepkemoi Kibet; Nancy Wanyonyi; James Mugisha Journal: Pan Afr Med J Date: 2017-02-28
Authors: Brendon Stubbs; Nicola Veronese; Davy Vancampfort; Trevor Thompson; Cristiano Kohler; Patricia Schofield; Marco Solmi; James Mugisha; Kai G Kahl; Toby Pillinger; Andre F Carvalho; Ai Koyanagi Journal: Sci Rep Date: 2017-08-02 Impact factor: 4.379